Novartis US’ Post

The Cost of Cancer Treatment in India: Exploring Healthcare Options: https://lnkd.in/gRFKPDNQ

#WorldCancerDay demonstrates the power of collaboration in the effort to reduce the global impact of cancer and #CloseTheCareGap for the millions of people impacted worldwide.     Our commitment to delivering new value to patients starts with listening to their needs and garnering insights from physicians, care teams, advocacy groups and researchers in the oncology community so we can better develop new therapeutic standards of care. Learn how we are pioneering new pathways in oncology to help redefine what’s possible for patients facing unmet needs: https://bit.ly/3OuKrPQ

On #WorldPancreaticCancerDay, we raise awareness about pancreatic cancer and its impact on patients worldwide. At nference, we're dedicated to advancing #pancreaticcancer research through #AI-driven insights and collaborations, with the goal of improving early detection, treatment options, and patient outcomes. #Healthcare #HealthTech #ClinicalTrials #MedicalAffairs #LifecycleManagement #FederatedAI #data #healthtech #RWE

Today, let's face the hard truth: 80% of cancer deaths happen in low- and middle-income countries. As a patient advocate, who was born in a LMIC my heart breaks for those facing barriers to care. Pharma leaders, it's time to act! Let's #CloseTheCareGap and ensure every patient gets the treatment they need and that no patient is left behind. Join the movement for change: https://lnkd.in/eWtd-KP8 #WorldCancerDay #PatientAdvocacy #LowMiddleIncomeCountries

I would like to share a few key takeaways after my participation at the European Hematology Association (EHA), more precisely at the session organized with Acute Leukemia Advocates Network (ALAN), a patient organization we collaborate with. This session underscored the significance of engaging patient organizations in clinical trials, especially in selecting Patient-Reported Outcomes (PROs)."   What are the Patient Reported Outcomes (PROs) best practices?   📌 Crucial role of engaging patients in clinical trials from the beginning 📌 Need to assess the Family Reported Outcomes 📌 Interest of using PROs in routine practice 📌 Ensure relevance of PROs for patients with adapted questionnaire 📌 Convey the purpose and benefit of PROs to patients   I would like to thank Sam Salek and Samantha Nier for their valuable insights.   #PatientReportedOutcome #PatientInsights #PatientOrganization #WeAreServier

ecancer.org https://lnkd.in/e9gceuTX Challenges and opportunities in NMIBC management across Latin America: insights from healthcare providers and a patient advocacy group Non-muscle invasive bladder cancer (NMIBC) is characterised by high rates of recurrence and progression, requiring substantial healthcare resources. In Latin America, the incidence of NMIBC is set to increase due to an aging population and lifestyle changes. To better understand the current challenges for NMIBC treaters and patients, a mixed-methods approach was leveraged combining secondary research with qualitative interviews from healthcare providers in Brazil, Colombia, Mexico and Argentina. Our analysis found that significant challenges persist across the region, particularly due to Bacillus Calmette-Guérin shortages, inconsistent adherence to clinical guidelines and significant socioeconomic disparities for patients accessing healthcare services. Addressing these challenges requires improved patient advocacy, strategic use of clinical trials and better resource distribution to enhance NMIBC management across Latin America.

In this interview, Dr. Meropol speaks to access to oncology clinical trials, representation in clinical trials, and technology in clinical trials. Timely topics for the healthcare industry. I encourage you to give this a read!

As #oncology embraces #valuebasedcare,Flatiron Health facilitates the transition from fee-for-service to complex VBC models, ensuring #communitypractices adeptly manage program demands and navigate increased #risk. https://lnkd.in/g4gfqpnv #cancer #Reimbursements #oncology #healthcare #HealthTech

Great podcast listen here about the importance of representation in oncology clinical trials, the role of technology in clinical trials, creating more access to clinical trials, and improving clinical trial design.

In recent years, breakthrough treatments have emerged for #myeloma, substantially elevating survival rates and offering patients with #MultipleMyeloma — a rare and challenging #BloodCancer — the gift of time. During #MyelomaACTIONMonth, we’re dedicated to amplifying awareness and fostering support for those affected by this condition.   At BC Platforms, we empower patients and clinicians with #RealWorldData, which offers tangible results for those affected by #MM through: 🔷 Improving the understanding of treatment outcomes in diverse populations, 🔷 Accelerating #research and #development of new, effective treatments, 🔷 Facilitating #PersonalizedMedicine and treatment based on large data analytics.   📑 Learn more / Download Learn more about BC Platforms' representative experience in #oncology by downloading our #RWD Availability Snapshot: https://bit.ly/3IIiQYn